X0202 SCHEDULE 13G 0001569064 XXXXXXXX LIVE Common Stock, par value $0.0001 per share 06/15/2026 0001829802 Faeth Therapeutics, Inc. 81728A207 701 Tillery Street #12 #1010 Austin TX 78702 Rule 13d-1(c) Suvretta Capital Management, LLC b DE 0 2020103 0 2020103 2020103 7.8 IA OO Averill Master Fund, Ltd. b E9 0 1722652 0 1722652 1722652 6.7 CO Aaron Cowen b X1 0 2020103 0 2020103 2020103 7.8 IN HC Faeth Therapeutics, Inc. 701 Tillery Street #12 #1010, Austin, Texas 78702 The persons filing this Schedule 13G are Averill Master Fund, Ltd., a Cayman Islands exempted company ("Averill Master Fund"), Suvretta Capital Management, LLC, a Delaware limited liability company ("Suvretta Capital"), and Aaron Cowen ("Mr. Cowen") (collectively, the "Reporting Persons"). The agreement among the Reporting Persons to file this Schedule 13G jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, is attached as Exhibit A hereto. The CUSIP provided in this statement is the CUSIP for shares of common stock, par value $0.0001 per share ("Common Stock") of Faeth Therapeutics, Inc. (the "Issuer"). The address of the principal office of (i) Averill Master Fund is c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands, and (ii) each of Suvretta Capital and Mr. Cowen is c/o Suvretta Capital Management, LLC, 540 Madison Avenue, 7th Floor, New York, New York 10022. Averill Master Fund is a Cayman Islands exempted company. Suvretta Capital is a Delaware limited liability company. Mr. Cowen is a United States citizen. Y Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference herein. Mr. Cowen is the control person and managing member of Suvretta Capital and may be deemed to control Averill Master Fund. Mr. Cowen disclaims beneficial ownership of all shares of Common Stock held by Averill Master Fund, other than to the extent of any pecuniary interest therein. Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission that any Reporting Person or any of its affiliates is the beneficial owner of any shares of Common Stock for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference herein. The percentage set forth in Row 11 of each Reporting Person's cover page is based on 25,778,754 shares of Common Stock outstanding as of June 15, 2026, as reported by the Issuer in its Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2026. Suvretta Capital Management, LLC - 7.8% Aaron Cowen - 7.8% Averill Master Fund, Ltd. - 6.7% Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the number of securities of the Issuer beneficially owned by such Reporting Person as to which such Reporting Person has the sole power to vote or to direct the vote and is incorporated by reference herein. Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the number of securities of the Issuer beneficially owned by such Reporting Person as to which such Reporting Person has the shared power to vote or to direct the vote and is incorporated by reference herein. Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the number of securities of the Issuer beneficially owned by such Reporting Person as to which such Reporting Person has the sole power to dispose or to direct the disposition of and is incorporated by reference herein. Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the number of securities of the Issuer beneficially owned by such Reporting Person as to which such Reporting Person has the shared power to dispose or to direct the disposition of and is incorporated by reference. Y N All of the securities reported in this Schedule 13G are directly owned by advisory clients of Suvretta Capital Management, LLC. None of those advisory clients, other than Averill Master Fund, may be deemed to beneficially own more than 5% of the Common Stock. N Please see Exhibit B attached hereto. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Exhibit A - Joint Filing Agreement Exhibit B - Control Person Identification Suvretta Capital Management, LLC /s/ Andrew Nathanson 06/23/2026 Averill Master Fund, Ltd. /s/ Andrew Nathanson 06/23/2026 Aaron Cowen /s/ Aaron Cowen 06/23/2026